AKT1 and prostate carcinoma: BAY1125976 inhibits broadly growth of human cancer cell lines and tumor xenografts, including the KPL-4 breast cancer model (PIK3CA H1074R mutant), the MCF7 and HBCx-2 breast cancer models, the Akt E17 K mutation-driven prostate cancer (LAPC-4) and anal cancer (AXF984) model [141].